Evidence map›Paper›PMID 41632128›Full record

ArticleJAMA network open2025

Use of Ursodeoxycholic Acid and Cancer Risk for Patients With Primary Biliary Cholangitis.

Lyra Su, Parth Jagrut Patel, Xiang Shu

Erratum issuedAbstract read
In one paragraph

Article in JAMA network open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Lyra SuDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.
Parth Jagrut PatelRowan-Virtua School of Osteopathic Medicine, Sewell, New Jersey.
Xiang ShuDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
Circulating metabolites as novel risk biomarkers for gastric cancer: a large multi-center prospective investigationR37CA283041 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Xiang Shu · 2024 to 2026
$2.2M
Uncovering Roles of Metabolites in Colorectal Cancer EtiologyR00CA230205 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI SHU, XIANG · 2020 to 2022
$888k
Prospective metabolomics investigation of gastric cancer risk in African Americans and European Whites with a low socioeconomic statusR56CA283041 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI SHU, XIANG · 2023 to 2023
$300k
NCI NIH HHS P30 CA008748NCI NIH HHS R00 CA230205NCI NIH HHS R37 CA283041NCI NIH HHS R56 CA283041
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID41632128
PMCPMC12717617

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.